Business
Definium Therapeutics Appoints Roger Adsett to Board of Directors
NEW YORK, January 29, 2026--Definium Therapeutics, Inc. (formerly Mind Medicine (MindMed) Inc.) today announced the appointment of Roger Adsett to its Board of Directors effective immediately.
About this update from Insmed Incorporated
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":5705,"height":1320,"url":"https://media.zenfs.com/en/business-wire.com/4ec22fdcfbc97180255d6baef5b494ba"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/1vWAywUbieabElJlAvY3cw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTIyMjtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/4ec22fdcfbc97180255d6baef5b494ba","width":960,"height":222},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/xJSk7mRmxExyc3cWkRhv0A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD01NTY7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/4ec22fdcfbc97180255d6baef5b494ba","width":1200,"height":278}},"lazy":false},{"type":"text","content":"Seasoned biopharmaceutical leader brings deep commercial, operational, and launch expertise to support Definium’s next phase of growth","length":134,"tagName":"p","attribs":{}},{"type":"text","content":"NEW YORK, January 29, 2026--(BUSINESS WIRE)--Definium Therapeutics, Inc. (formerly Mind Medicine (MindMed) Inc.) today announced the appointment of Roger Adsett to its Board of Directors effective immediately.","length":209,"tagName":"p"},{"type":"text","content":""We are thrilled to welcome Roger to our Board of Directors," said Rob Barrow, Chief Executive Officer of Definium Therapeutics. "Roger is a respected and proven leader with deep experience building high-performing commercial organizations and guiding transformational therapies from launch to meaningful market impact. At Insmed, he’s led the development of world-class commercial and operational capabilities supporting the company on its mission to transform the lives of patients facing serious diseases. His ability to translate innovative science into disciplined, large-scale commercial execution will be especially valuable as we approach three anticipated Phase 3 readouts in 2026 and prepare to bring transformative therapies to patients."","length":769,"tagName":"p"},{"type":"text","content":"Mr. Adsett is a highly accomplished biopharmaceutical executive with more than two decades of experience leading landmark drug launches, scaling global commercial organizations, and helping companies establish leadership positions within their therapeutic areas, including specialty, rare disease, and primary care markets.","length...